Proteotype Diagnostics plans a new multi-study clinical program to support its multicancer early detection (MCED) test, Enlighten, including a study geared toward its CE-IVDR submission. The Cambridge-based company also plans another study to optimize its platform as it prepares for broader clinical commercialization. CEO Wesley Sukdao said financing discussions are underway, framing the work as the next step in clinical and regulatory product development. Proteotype’s platform is built around amino-acid residue biomarker signatures of cancer-specific immune activation and is supported by earlier validation work described in Nature Communications. The company’s narrative centers on assay performance across distinct disease contexts—including cancer, autoimmune, and infectious diseases—while moving toward the regulatory-grade evidence typically required for European in vitro diagnostic labeling.